3.4.8. general recommendations precautions stone removal. 3.4.8.1. antibiotic therapy urinary tract infections always treated stone removal planned. patients clinically significant infection obstruction, drainage performed several days starting stone removal. urine culture urinary microscopy performed treatment . peri-operative antibiotic prophylaxisthe available evidence prevention infection following urs percutaneous stone removal, remains limited . administration single dose prophylactic antibiotics prior ureteroscopy found sufficient [302-304]. review large database patients undergoing pcnl, found patients negative baseline urine culture, antibiotic prophylaxis significantly reduced rate postoperative fever complications . based three meta-analyses, pooling data small series varying quality extended course pre-operative prophylactic antibiotics prior pcnl compared single dose anaesthesia significantly reduced post-operative sepsis fever patients priori increased risk infection . rct including moderate high-risk infection patients (patients pre-operative stents/nephrostomy positive urine culture), seven-day course pre-operative antibiotics reduced risk post-pcnl sepsis threefold comparison two-day course . studies specify risk patient population, single dose antibiotic prophylaxis administered induction equivalent extended pre-operative course . contrast this, prolonged course post-operative antibiotics superior single dose pre-operatively . national regional antibiotic resistance patterns differ significantly, choice antibiotic prophylaxis tailored institutional regional antimicrobial susceptibility . recommendationsstrength ratingobtain urine culture perform urinary microscopy treatment planned.strongexclude treat urinary tract infections prior stone removal.strongoffer peri-operative antibiotic prophylaxis patients undergoing endourological treatment.strong 3.4.8.2. antithrombotic therapy stone treatment patients bleeding disorder, receiving antithrombotic therapy, referred internist appropriate therapeutic measures deciding stone management [310-314]. patients uncorrected bleeding disorder, following elevated risk haemorrhage perinephric haematoma (pnh) (high-risk procedures): swl (hazard ratio pnh 4.2 anti-coagulant/anti-platelet medication) pcnl;percutaneous nephrostomy;laparoscopic surgery;open surgery . shock wave lithotripsy feasible safe correction underlying coagulopathy . case uncorrected bleeding disorder continued antithrombotic therapy, urs, contrast swl pcnl, might offer alternative approach since associated less morbidity [318-320]. despite appropriate cessation anti-platelet agents, following standardised protocols, prolonged haematuria tube drainage pcnl reported . data flexible urs available support superiority urs treatment proximal ureteral stones . although urs safe patients bleeding disorders anticoagulation, individualised patient approach necessary . table 3.9: risk stratification bleeding risk stratification bleedinglow-risk bleeding procedurescystoscopyflexible cystoscopyureteral catheterisationextraction ureteral stentureteroscopyhigh-risk bleeding proceduresshock wave lithotripsypercutaneous nephrostomypercutaneous nephrolithotomy table 3.10: suggested strategy antithrombotic therapy stone removal [312-314] (in collaboration cardiologist/internist weigh risks benefits discontinuation therapy, vs. delaying elective surgical procedures). suggested strategy antithrombotic therapy stone removalmedication/agentbleeding risk ofplanned procedurerisk thromboembolismlow riskintermediate riskhigh riskwarfarindabigatranrivaroxabanapixabanlow-risk proceduremay continuedbridging therapybridging therapyhigh-risk proceduremay temporarily discontinued appropriate interval.bridging therapy strongly recommended.bridging therapybridging therapyaspirinlow-risk procedurecontinuecontinueelective surgery: postpone.non-deferrable surgery: continue.high-risk procedurediscontinueelective surgery:postpone.non-deferrablesurgery: continue, possible.elective surgery:postpone.non-deferrablesurgery: continue.thienopyridineagents (p2y12receptor inhibitors)low-risk procedurediscontinuefive days beforeintervention.resume within24-72 hours loading dose.continueelective surgery: postpone.non-deferrable surgery: continue.high-risk procedurediscontinuefive days intervention resume within 24-72 hours loadingdose.elective surgery:postpone.non-deferrablesurgery: discontinuefive days beforeprocedure andresume within 24-72 hours loading dose.bridging therapy-glycoprotein iib/iiia inhibitors aspirin discontinued.elective surgery:postpone.non-deferrable surgery: discontinue five days procedure resume within 24-72 hours, loading dose.bridging therapy-glycoprotein iib/iiiainhibitors. 3.4.8.2.1. summary evidence recommendations antithrombotic therapy stone treatment summary evidenceleactive surveillance indicated patients high risk thrombotic complications presence asymptomatic calyceal stone.4the temporary discontinuation, bridging antithrombotic therapy high-risk patients, discussed internist.3retrograde (flexible) urs stone removal associated less morbidity patients antithrombotic therapy cannot discontinued.2a recommendationsstrength ratingoffer active surveillance patients high risk thrombotic complications presence asymptomatic calyceal stone.weakdecide temporary discontinuation, bridging antithrombotic therapy high-risk patients, consultation internist.strongretrograde (flexible) urs preferred intervention stone removal essential antithrombotic therapy cannot discontinued since associated less morbidity.strong 3.4.8.3. obesity high bmi pose higher anaesthetic risk lower success rate swl pcnl may influence choice treatment . 3.4.8.4. stone composition stones composed brushite, calcium oxalate monohydrate, cystine particularly hard, well homogeneous stones high density ncct . percutaneous nephrolithotomy rirs urs alternatives removal large swl-resistant stones. recommendationsstrength ratingconsider stone composition deciding method removal, based patient history, former stone analysis patient hounsfield unit unenhanced computed tomography.strongattempt dissolve radiolucent stones.strong 3.4.8.5. contraindications procedures contraindications extracorporeal swlthere several contraindications use extracorporeal swl, including: pregnancy, due potential effects foetus ;bleeding disorders, compensated least 24 hours 48 hours treatment ;uncontrolled utis;severe skeletal malformations severe obesity, prevent targeting stone;arterial aneurysm vicinity stone ;anatomical obstruction distal stone. contraindications ursapart general problems, example general anaesthesia untreated utis, urs performed patients without specific contraindications. contraindications pcnlpatients receiving anti-coagulant therapy must monitored carefully pre- post-operatively. anti-coagulant therapy must discontinued pcnl . important contraindications include: untreated uti;tumour presumptive access tract area;potential malignant kidney tumour;pregnancy (section 3.4.14.1). general contraindication endourological proceduresendourological interventions adversely affect renal function although care must taken poor pre-operative renal function, diabetes hypertension . however, meta-analysis, based low quality evidence, suggests patients impaired renal function stone disease, may fact benefit procedure preserve increase renal function .